Loading lessons…
Loading lessons…
Curated lessons across 8 learning paths — from first concepts to trial summaries and practical protocols. Pick your level, follow the curriculum, and build real understanding.
Where are you starting?
Choose a learning path below or search the library. Progress saves in your browser.
Prefer timeline chaos? Peptide X Quiz · Literacy certify
Pick a track — progress rings update as you complete lessons.
33 lessons
10mTwo antibodies that block the myostatin/activin pathway are being tested alongside GLP-1 drugs to protect lean mass. Bimagrumab's phase 2 BELIEVE trial is published in Nature Medicine. Apitegromab is FDA-approved, but only for spinal muscular atrophy. Neither is a peptide or a pill.
7mCT-G32, also called SCO-940, is a preclinical four-receptor obesity candidate. The sponsors reported rat and monkey data at TIDES Europe in November 2026 and plan a US IND in February 2027. Here's how to place that news on the drug-development ladder.
9mUBT251 is a once-weekly GLP-1, GIP and glucagon receptor agonist in development in China. Two phase 2 trials published in Cell Metabolism in October 2026. Here is what they measured, how to read the numbers, and why they can't be ranked against retatrutide.
9mGHK-Cu is a small copper-binding peptide with decades of lab research and a thin human record. Here's what it is, why topical and injectable use are different questions, and where FDA stands in 2026.
9mRetatrutide is Lilly's investigational GIP, GLP-1 and glucagon receptor agonist. Understand the trial findings, how it differs from approved medicines, and why it is not available by prescription.
12mThe only peptides with large controlled trials for weight loss are the GLP-1 class: semaglutide, tirzepatide, and the oral options approved in 2025 and 2026. Retatrutide is next but still investigational. Here's how they work, what the trials showed, and how to access them through a licensed clinician.
9mTirzepatide is the dual GIP/GLP-1 receptor agonist behind Mounjaro (type 2 diabetes) and Zepbound (weight management, sleep apnea). Here's what it is, what the trials showed, how it compares with semaglutide and retatrutide, and how to get evaluated by a licensed clinician.
8mFoundayo is the brand name for orforglipron — a once-daily oral small-molecule GLP-1 approved in April 2026. Here's what the pill is, how it differs from injectables, and what trials studied — not a dosing prescription.
8m5-Amino-1MQ dosage searches grew more than 1,400 percent. The stack page already ranks. This companion stays on milligram ranges and oral versus subQ handling language.
10mMost BPC-157 dose threads treat forum tables as fact. This guide separates published animal and limited human data from observational ranges people log, without turning either into a protocol.
10mCJC-1295 dose threads often ignore whether the vial is the albumin-binding DAC form or Mod GRF 1-29. The papers treat those as different exposure patterns. So should any educational chart.
9mEpitalon dose threads sell multi-day courses as if they were modern RCTs. The published record is older, smaller, and more specific than the calendars imply.
9mIpamorelin is discussed as a selective ghrelin-receptor secretagogue with a quieter side-effect story than older GHRPs. The papers describe pharmacology. Forum charts describe habits.
8mNAD+ 1000 mg reconstitution searches want a 1 g calculator. The existing NAD+ guide covers smaller vials. This page does the 1000 mg arithmetic and keeps it educational.
9mQueries about how much BAC water for a 20 mg retatrutide vial want a calculator. This page shows the arithmetic and why trial pens and unlabeled cakes are not the same object.
9mSermorelin is the short GHRH analog older clinic pages still treat as the gentle GH option. The literature is real. The nightly microgram charts are practice culture, not a modern phase 3 program.
10mTB-500 threads collapse a fragment, a parent peptide, and forum loading weeks into one chart. The papers are more specific, and the human dosing story is thinner than the marketing.
9mTesamorelin is one of the few GHRH analogs with an FDA-labeled daily milligram figure. That number belongs to a specific product and indication. It does not automatically travel to an unlabeled vial.
9mThymosin alpha-1 has a thicker clinical literature than most research-vial peptides. The milligram figures in those papers still belong to study and labeled-product contexts, not an unlabeled cake.
11mMid-40s and new to peptides? This guide explains how beginners typically choose a conservative first protocol using goals, compound class, published ranges, and tracking — without inventing a prescription.
12mKisspeptin-10 sits upstream of GnRH in reproductive endocrinology research. This guide explains mechanism, what people track, dosing as community discussion only, and why Kispeptin searches miss the mark.
10mDry powder vs mixed liquid changes everything — concentration, storage, and beyond-use timing. This guide explains lyophilized vs reconstituted peptides and what people mean by constituted vs non.
12mReta plus Tesa is one of the most asked stack questions in 2026. This guide explains why people combine metabolic and visceral-fat peptides, what to track, and why same-syringe mixing is usually avoided.
11mA 10 mg Selank vial looks simple until you mix the wrong diluent volume or chase a Sealink listing. This guide covers BAC reconstitution math, route context, and tracking habits — educational only, not medical advice.
10mRetatrutide may dominate the weight-loss discussion, but the market debate is really about quality control, documentation, and whether a plan can survive real life.
8mSearching for eloralintide dosage? Here is the clean map of Phase 2 once-weekly doses, titration arms, and weight-loss results — framed as clinical education, not a DIY protocol.
5mEducational reconstitution math for NAD+ vials: how diluent volume changes concentration, with worked examples that are not a universal mix or dosing protocol.
8mConfused about peptide compounding categories? This guide breaks down 503a compounding pharmacies, 503b outsourcing facilities, and why “research use only” is not a consumer pathway PeptIQ endorses.
10m5-Amino-1MQ blocks NNMT instead of suppressing appetite. This guide covers oral dosing ranges and why people stack it with GLP-1s and MOTS-C for stubborn visceral fat.
9mMost peptide users eventually ask: BAC or sterile water? This guide breaks down tradeoffs, timing, and practical decision rules with a peptide-by-peptide reference workflow.
10mKLOW is a vendor name for a four-peptide blend: BPC-157, TB-500, GHK-Cu and KPV in one vial. Here's what each ingredient is, what the research actually covers, how KLOW differs from GLOW and Wolverine, and where it stands with FDA.
7mMOTS-C is one of the most studied mitochondrial peptides for metabolic health and longevity. This guide covers dosing ranges, frequency, timing, stacking options, and what to track on protocol.
8mNAD+ and peptides like BPC-157, MOTS-C, and KLOW work through completely different pathways — which is exactly why they stack well. Here's how to combine them safely and effectively.
Also available at /blog for legacy links.